Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)โข Click on a phase to view related trials
Evaluation of an Anti-TREM-1 Treatment on an ex Vivo Human Intestinal Model
- Conditions
- Inflammatory Bowel Diseases
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Inotrem
- Target Recruit Count
- 40
- Registration Number
- NCT06580418
- Locations
- ๐ฎ๐น
IRCCS San Raffaele, Milano, Italy
Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Inotrem
- Target Recruit Count
- 220
- Registration Number
- NCT04429334
- Locations
- ๐ง๐ช
Clinique universitaire Saint-Luc, Brussels, Belgium
๐ง๐ชZiekenhuis Oost-Limburg, Genk, Belgium
๐ซ๐ทCHU Angers, Angers, France
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
- Conditions
- Shock, Septic
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Inotrem
- Target Recruit Count
- 355
- Registration Number
- NCT04055909
- Locations
- ๐ง๐ช
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
๐ง๐ชZiekenhuis Oost-Limburg, Genk, Belgium
๐ง๐ชUZ Gent, Gent, Belgium
Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Inotrem
- Target Recruit Count
- 27
- Registration Number
- NCT03463044
- Locations
- ๐ฌ๐ง
Richmond Pharmacology Ltd., Croydon, United Kingdom
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock
- Conditions
- Shock, Septic
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Inotrem
- Target Recruit Count
- 50
- Registration Number
- NCT03158948
- Locations
- ๐ง๐ช
Cliniques Universitaires Saint-Luc (there may be other sites in this country), Brussels, Belgium
๐ซ๐ทInserm Clinical Investigational Center, CHU Dupuytren (there may be other sites in this country), Limoges Cedex, France
๐ณ๐ฑRadboudumc (there may be other sites in this country), Nijmegen, Netherlands
News
Inotrem's Precision Medicine Strategy Shows Breakthrough Results for Septic Shock Treatment with Nangibotide
Inotrem published breakthrough precision medicine strategy for nangibotide in Intensive Care Medicine, demonstrating significant clinical improvements in septic shock patients with elevated sTREM-1 biomarker levels.